James DArecca - 15 May 2023 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
EVP, Chief Financial Officer
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. D'Arecca
Issuer symbol
HAE
Transactions as of
15 May 2023
Net transactions value
-$31,134
Form type
4
Filing time
17 May 2023, 16:26:31 UTC
Previous filing
04 May 2023
Next filing
03 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Award +4,205 +41% 14,451 15 May 2023 Direct F1, F2, F3
transaction HAE Common Stock Tax liability $31,134 -349 -2.4% $89.21 14,102 16 May 2023 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Award $0 +9,502 $0.000000 9,502 15 May 2023 Common Stock 9,502 $89.16 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3 This number includes unvested RSUs previously reported.
F4 Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.
F5 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.